Member Info for Winit

H50......thanks very much for the link, I think this could be quite a significant positive for Greenroc.

TopLocks from some brief research i understand synthetic grahite to be considerably more expensive due to the high

manufacturing energy usage. I'm thinking in contrast the

Norway plan minimise energy costs thro' the cheap

electrical supply costs that exist there.

Eeko...I don't have access to the Elric podcast, would you be so kind as to summarise it please.

Although I agree the article you posted involves the use of Creo's Microblate flex device, from our perspective it's not directly referred to ...pity.

I'm hopeful that a NICE MTG would be seen as an important step forward and start to generate a more immediate interest in Creo.

The NICE website shows process for receiving MTG Medical Technologies Guidance to be 38 weeks. Based on 1 June assessment start date (rns'd) if process has gone ahead to schedule the output will be due about now - mid March.

Assuming a positive outcome do you folks believe this will elevate the SP?

I consider this appt and Christina's statements within the rns very significant. I hope and expect this will mean we will not see the share price as low as this again..

Great find Kipper, little old Dest....what company to be associated with. Fingers crossed for medical users and investors alike.

Thanks gmcc for this specufically and your continued research and posting. Perhaps Avacta's affimers interests should not be underestimated as part of the wider picture.

Profcheese, thanks for the post. Very useful thread.

Best wishes to all.

Great thread this, it just neatly summarises the fantastic opportunity for AVA6000.

Many thanks to posters.

It's a sure red board for me.

Https://x.com/aw1321999/status/1734876804916117877?s=03

Great post: I think you have possibly hit the nub of the matter. It is no coincidence that this 2 weekly dosing regime has been introduced. With high FAP tumours case selection and a increased dosing frequency I am very optimistic in seeing significant imorovement in efficacy v standard dox.

It begs the question if the exquisite targetting being shown could not only lead to improved efficacy from the 2 week trial but also suggest a trial on say a 1 weekly or 10day regime ! Why not if the frequency of dosing is a major factor in reducing (even moving onto eliminating?) tumour size.

So there's been a bit of negativity around but come on troops keep together and retain faith in just how good this might be (and very possibly in not too long a timescale). If the theory works then is it not a reasonable assertion that we will see significant efficacy results relatively soon and the media/partner etc attention that would surely bring.

In the interest of patients lives I would expect the US screening/recruiting will crack on at pace.

Keep up the fantastic work Avacta.

Good spot that.

Creo discussion starts around 35mins to help folks.

Apologies there fat fingers, sure you get the jist !!

Let's hope there's some real uptake from the II's etc. I am expecting the feedback from the consultants/clinicians to be quite impressive.

I also wonder how things are progressing with the robotics side, with the large size of the companies involved, it's a very interesting area.

Let's hope for an up tick in SP as Creo gets it's name out there.

"The Company will provide greater detail on the commercial and clinical progress of its products..."

Is that potentially at odds with:

The event is open to institutional investors, sell-side analysts and media only. To request a place at the event, please contact Walbrook PR on +44 (0)20 7933 8780 or creo@walbrookpr.com.

No new material information will be disclosed during the event.

From today's rns:

Capital Markets Day

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that it is hosting its Capital Markets Day today at the offices of Deutsche Numis, London at 3pm GMT.

The Company will provide greater detail on the commercial and clinical progress of its products and will feature presentations from a number of NHS clinicians who are using Creo's products in practice. The agenda of the event will include presentations from:

· Dr Sal Khalid, Consultant Gastroenterologist and Clinical Lead for Endoscopy at The Pennine Acute Hospitals NHS Trust: "How Speedboat Submucosal Dissection is helping Oldham tackle bowel cancer"

· Dr Adolfo Parra-Blanco, Consultant Gastroenterologist, Hepatologist, Nottingham NHS Treatment Centre: "Why Speedboat is so effective at reducing patient complications in the Upper GI tract"

· Mr Tom Routledge, Consultant Thoracic Surgeon, Guy's and St. Thomas' NHS Foundation Trust: "Creo Medical - A surgeon's perspective"

The event is open to institutional investors, sell-side analysts and media only. To request a place at the event, please contact Walbrook PR on +44 (0)20 7933 8780 or creo@walbrookpr.com.

No new material information will be disclosed during the event.

"several patients in cohort 5 and earlier cohorts remain on treatment as their disease has not progressed"

Above from RNS in June.

How great if that remains the same or better !!

"With this news, the accelerated timeframes will now see Creo, clinicians and patients reaping the benefits of widespread commercialisation of Speedboat UltraSlim in both Europe and the US in 2024."

Early 2024 has been stated elsewhere, I feel this news is quite significant and (if I read it right) shows the eagerness of the regulatory bodies to support CREO in getting their impressive tech into use for a wider range of surgical applications. Seems great to me !

Doesn't feel like this is going lower than 150, perhaps a rise into the afternoon.

With CMR surgical to consider also (another very large robotic based med device company) little Creo are interfacing with some similar? big boys.

It feels like an interesting situation. I expect/hope something significant will come from these relationships.

Can Intuitive and CMR be considered competitors ?